VE Paz

VE Paz is a biotechnology company focused on developing next-generation live biotherapeutic products (LBPs) for the treatment of cancer and other serious diseases. The company leverages a proprietary platform to design defined bacterial consortia that modulate the host immune system and enhance the efficacy of existing therapies, such as checkpoint inhibitors. VE Paz's lead programs are centered on immuno-oncology, aiming to transform the gut microbiome into a potent tool for anti-tumor activity. By utilizing a rational design approach, the company seeks to provide standardized, scalable, and effective microbial therapies that overcome the limitations of traditional fecal microbiota transplants.